Patents Represented by Attorney, Agent or Law Firm John D. Conway
-
Patent number: 7091227Abstract: The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.Type: GrantFiled: February 6, 2001Date of Patent: August 15, 2006Assignee: Abbott GmbH & Co. KGInventors: Barbara Scott, Lee D. Arnold, Anna M. Ericsson, Kevin P. Cusack
-
Patent number: 7071199Abstract: The present application is directed to a compound of Formula (I) as defined herein which are useful as kinase inhibitors.Type: GrantFiled: September 15, 2000Date of Patent: July 4, 2006Assignee: Abbott GmbH & CCo. KGInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Helen Twigger, Stephen St. Gallay
-
Patent number: 7060822Abstract: Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.Type: GrantFiled: July 24, 2000Date of Patent: June 13, 2006Assignee: Abbott GmbH & Co. KGInventors: Lee Arnold, Marina Moran Moset, Jose Maria Castellano Berlanga, Isabel Fernandez, David J. Calderwood, Paul Rafferty
-
Patent number: 6992216Abstract: A method for reducing the particle size of amino acid crystals using ultrasound is discussed.Type: GrantFiled: January 7, 2003Date of Patent: January 31, 2006Assignee: Abbott GmbH & Co. KGInventors: Siegfried Bechtel, Matthias Rauls, Richard Van Gelder, Seth C. Simpson
-
Patent number: 6803387Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating fibromyalgia or neuropathic pain, such as pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.Type: GrantFiled: March 17, 2000Date of Patent: October 12, 2004Assignee: Abbott GmbH & Co. KGInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Edward Chong
-
Patent number: 6713474Abstract: Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant rejections and imflammatory disorders.Type: GrantFiled: March 29, 2000Date of Patent: March 30, 2004Assignee: Abbott GmbH & Co. KGInventors: Gavin C. Hirst, David Calderwood, Rainer Munschauer, Lee D. Arnold, David N. Johnston, Paul Rafferty
-
Patent number: 6660744Abstract: The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.Type: GrantFiled: September 15, 2000Date of Patent: December 9, 2003Assignee: Abbott GmbH & Co. KGInventors: Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Neil Wishart, Lee D. Arnold, Michael M. Friedman
-
Patent number: 6617360Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.Type: GrantFiled: October 30, 2000Date of Patent: September 9, 2003Assignee: Knoll AktiengesellschaftInventors: Clifford James Bailey, Robert Brian Jones, Helen Christine Jackson
-
Patent number: 6462036Abstract: This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.Type: GrantFiled: May 17, 2000Date of Patent: October 8, 2002Assignee: BASF AktiengesellschaftInventors: Kevin J. Doyle, Paul Rafferty, Robert W. Steele, David J. Wilkins, Lee D. Arnold, Michael Hockley, Anna M. Ericsson, Nobuhiko Iwasaki, Nobuo Ogawa
-
Patent number: 6451834Abstract: Chemical compounds that are derivatives of indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole are inhibitors of tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in hyperproliferative, angiogenic or in vascular hyperpermeability processes. Thus, these chemical compounds can ameliorate disease states where tumor formation, metastasis, angiogenesis, vascular hyperpermeability or endothelial cell proliferation is a factor.Type: GrantFiled: April 3, 2000Date of Patent: September 17, 2002Assignee: BASF AktiengesellschaftInventors: Lee D. Arnold, Yajun Xu, Teresa Barlozzari
-
Patent number: 6441046Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl ]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating metabolic disorders, such as increased non-exercise activity thermogenesis or increased metabolic rate.Type: GrantFiled: March 17, 2000Date of Patent: August 27, 2002Assignee: Abbott GmbH & Co. KGInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6433020Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating cardiovascular disease, such as dyslipidaemia or carotid intimal medial thickening.Type: GrantFiled: March 17, 2000Date of Patent: August 13, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6403650Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-4chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating pulmonary hypertension, particularly in patients who take certain anorectic medications.Type: GrantFiled: March 17, 2000Date of Patent: June 11, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6380260Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for decreasing platelet adhesiveness.Type: GrantFiled: March 17, 2000Date of Patent: April 30, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6376554Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate), including individual enantiomers and racemates thereof, is used for treating sexual dysfunction.Type: GrantFiled: March 17, 2000Date of Patent: April 23, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Sharon C. Cheetham, David J. Heal
-
Patent number: 6376551Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating chronic fatigue syndrome.Type: GrantFiled: March 17, 2000Date of Patent: April 23, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6376553Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating pain such as low back pain.Type: GrantFiled: March 17, 2000Date of Patent: April 23, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6376552Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating gallstones, particularly gallstones associated with weight loss or associated with gall bladder disease related to obesity.Type: GrantFiled: March 17, 2000Date of Patent: April 23, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6372798Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating hyperactivity disorders, such as attention deficit hyperactivity disorder and hyperkinetic disorder.Type: GrantFiled: March 17, 2000Date of Patent: April 16, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein
-
Patent number: 6372797Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating menstrual function and infertility.Type: GrantFiled: March 17, 2000Date of Patent: April 16, 2002Assignee: Knoll Pharmaceutical CompanyInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein